Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 193 300 KRW 0.42% Market Closed
Market Cap: 40.1T KRW
Have any thoughts about
Celltrion Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one Celltrion Inc stock under the Base Case scenario is 235 986.3 KRW. Compared to the current market price of 193 300 KRW, Celltrion Inc is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
235 986.3 KRW
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

13.9
P/S
P/S
Price to Sales
13.9
vs History
58
vs Industry
34
Median 3Y
11.3
Median 5Y
15.8
Industry
7.6
Forward
11.1
More Details
214.1
P/E
P/E
Price to Earnings
214.1
vs History
1
vs Industry
2
Median 3Y
43.5
Median 5Y
60.8
Industry
22.1
Forward
74.6
More Details
53.7
P/OCF
P/OCF
Price to OCF
53.7
vs History
63
vs Industry
2
Median 3Y
69.3
Median 5Y
70.8
Industry
21.9
More Details
149.8
P/FCFE
P/FCFE
Price to FCFE
149.8
vs History
33
vs Industry
0
Median 3Y
51.2
Median 5Y
75.4
Industry
23.4
More Details
2.4
P/B
P/B
Price to Book Value
2.4
vs History
85
vs Industry
38
Median 3Y
5.2
Median 5Y
6.2
Industry
2.5
More Details
14.3
EV/S
EV/S
Enterprise Value to Sales
14.3
vs History
58
vs Industry
29
Median 3Y
11
Median 5Y
15.9
Industry
7.5
Forward
11.4
More Details
32.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
32.1
vs History
46
vs Industry
16
Median 3Y
21.7
Median 5Y
31.1
Industry
9.3
More Details
56.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
56.5
vs History
1
vs Industry
2
Median 3Y
26.1
Median 5Y
36.6
Industry
4.2
Forward
40.4
More Details
130.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
130.7
vs History
1
vs Industry
1
Median 3Y
35.2
Median 5Y
47.5
Industry
4
Forward
66.9
More Details
55
EV/OCF
EV/OCF
Enterprise Value to OCF
55
vs History
63
vs Industry
2
Median 3Y
70.8
Median 5Y
71.2
Industry
5.9
More Details
98.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
98.1
vs History
50
vs Industry
0
Median 3Y
95
Median 5Y
99.2
Industry
3.9
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
85
vs Industry
46
Median 3Y
3.9
Median 5Y
5.1
Industry
4.5
More Details

Multiples Across Competitors

Competitors Multiples
Celltrion Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Celltrion Inc
KRX:068270
40.1T KRW 13.9 214.1 56.5 130.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
36.2B EUR 19.4 -136.2 -110 -80.2
P/S Multiple
Revenue Growth P/S to Growth
KR
Celltrion Inc
KRX:068270
Average P/S: 3 457 241.2
13.9
153%
0.1
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.4
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
KR
Celltrion Inc
KRX:068270
Average P/E: 212.1
214.1
217%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -136.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
Celltrion Inc
KRX:068270
Average EV/EBITDA: 22
56.5
170%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -110 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
Celltrion Inc
KRX:068270
Average EV/EBIT: 36.9
130.7
229%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -80.2 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.